APO-ESCITALOPRAM 10 MG
ESCITALOPRAM (ESCITALOPRAM OXALATE) : 10 MG · DIN 02295016 · APOTEX INC
Health Canada status: MARKETED
What is APO-ESCITALOPRAM?
APO-ESCITALOPRAM 10 MG contains ESCITALOPRAM (ESCITALOPRAM OXALATE) : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02295016, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 10-Sep-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-ESCITALOPRAM used for?
Symptomatic relief of Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), and Obsessive-Compulsive Disorder (OCD) in adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02295016 |
|---|---|
| Brand name | APO-ESCITALOPRAM |
| Generic / active ingredient | ESCITALOPRAM (ESCITALOPRAM OXALATE) : 10 MG |
| Manufacturer | APOTEX INC |
| Strength | 10 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06AB10 ESCITALOPRAM |
| AHFS class | 28:16.04.20 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 10-Sep-2014 |
| Original market date | 2014-09-10 00:00:00 |
How is it administered?
Adults: 10 mg once daily (max 20 mg). Elderly/Hepatic impairment/CYP2C19 poor metabolizers: 5 mg once daily (max 10 mg). Administer with or without food. Taper gradually to discontinue.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in provided text (standard section 11 is listed in TOC but content not in snippet).
How is it supplied?
10 mg and 20 mg tablets: Blister packages of 30; Bottles of 100 and 500.
Contraindications
Hypersensitivity; Concomitant use of MAOIs, pimozide, or citalopram; Patients with known QT interval prolongation or congenital long QT syndrome.
Warnings and precautions
Increased risk of self-harm and suicidal thoughts. Risk of QT prolongation, abnormal bleeding, serotonin syndrome, and discontinuation symptoms. Caution in patients with cardiac disease or diabetes.
Is ESCITALOPRAM in shortage in Canada?
A Canadian shortage report is on file for this molecule: Anticipated — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N06AB10 ESCITALOPRAM. 47 of 101 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-ESCITALOPRAM | 10 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02434652 |
| ACH-ESCITALOPRAM | 20 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02434660 |
| ACT ESCITALOPRAM ODT | 10 MG | TABLET (ORALLY DISINTEGRATING) | TEVA CANADA LIMITED | MARKETED | DIN 02454297 |
| ACT ESCITALOPRAM ODT | 20 MG | TABLET (ORALLY DISINTEGRATING) | TEVA CANADA LIMITED | MARKETED | DIN 02454300 |
| AG-ESCITALOPRAM | 10 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02477742 |
| AG-ESCITALOPRAM | 20 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02477769 |
| AG-ESCITALOPRAM TABLETS | 10 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02510944 |
| AG-ESCITALOPRAM TABLETS | 20 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02510952 |
| APO-ESCITALOPRAM | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02295024 |
| AURO-ESCITALOPRAM | 10 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02397358 |
Who else supplies ESCITALOPRAM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ESCITALOPRAM appears in 1361 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.